Skip to main content

Table 1 Synthesis of the data reported in selected clinical trials. Terms in bold within the 'Intervention' column indicate the specific medical intervention/treatment assessed in the trial. Terms in bold within the 'Outcomes' column indicate the trial's endpoints

From: Targeted drugs and Psycho-oncological intervention for breast cancer patients

Study Intervention Patients group Number of patients Length of the study Outcomes
Miller et al. 2007 [9] Randomized, phase 3 trial. Metastatic breast cancer N = 722 (Control N = 354; Invervention N = 368) 2.5 years PFS> 5.9 months (p < 0.001)
Efficacy and safety on paclitaxel with or without bevacizumab OS >1.5 months (p < 0.16)
Spiegel et al. 2007 [33] Randomized prospective trial on supportive-expressive group therapy Metastatic breast cancer N = 125 (Control N = 61; Intervention N = 64) >1 year (14 years follow-up) OS <2.6 months (p = 0.73)
Kissane et al. 2007 [13] Randomized controlled trial on supportive-expressive group therapy Metastatic breast cancer (stage IV) N = 227 (Control N = 80; Intervention N = 147) >1 year (2 years follow-up) OS >5.7 months (p = 0.60)
EORTC QoL C-30
Social functioning scale F = 4.56 (p = 0.03), Impact of Event Scale F = 4.61 (p = 0.04)
Mini-MAC
helpless/hopelessness F = 4.89 (p = 0.03)
Von Minckwitz et al. 2012 [11] Randomized clinical trial on neoadjuvant therapy with or without bevacizumab Non-metastatic HER2-negative breast cancer N = 1948 (Control N = 969; Intervention N = 956) 2.5 years pCR >4 % (p = 0.04)
Bear et al. 2012 [10] Randomized clinical trial on neoadjuvant therapy with or without bevacizumab Non-metastatic HER2-negative breast cancer N = 1206 (Control N = 596; Intervention N = 595) 2.5 years pCR >6.3 % (p = 0.02)
Andersen et al. 2008 [14] Randomized clinical trial on psychological intervention Non-metastatic breast cancer (stage IIA, IIIA or IIIB) N = 227 (Control N = 113; Intervention N = 114) 1 year (11 years follow-up) OS >1.3 years (p = 0.016)
Kissane et al. 2004 [15] Randomized controlled trial on cognitive-existential group therapy Non-metastatic breast cancer (stage I or II) N = 303 (Control N = 149; Intervention N = 154) 2 years (5 years follow-up) OS <3.5 months (p = 0.31)